Discover
ONCO
Onconetix, Inc.
0.59
2 x 0.50
2 x 0.75
bid
ask
-
0.08
11.84%
2 @ 08:56 AM
0.80 +0.21 (35.86%)
| Ytd | -92.47% | |
| 1y | -98.00% |
0.57
day range
0.72
0.57
52 week range
74.38
| Open | 0.67 | Prev Close | 0.67 | Low | 0.57 | High | 0.72 | Mkt Cap | 407.09K |
| Vol | 1.30M | Avg Vol | 5.92M | EPS | -82.80 | P/E | N/A | Forward P/E | -0.41 |
| Beta | 3.73 | Short Ratio | 0.45 | Inst. Own | 7.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-31 | 50-d Avg | 2.36 | 200-d Avg | 10.76 | 1yr Est | 9.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-12-09 | 2024-09 | 0 | -2.24 | N/A | N/A |
| 2024-08-29 | 2024-06 | 0 | -9.2 | N/A | N/A |
| 2024-05-20 | 2024-03 | 0 | -6.4 | N/A | N/A |
| 2024-04-04 | 2023-12 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2023-09-13 | Maxim Group | Downgrade | Buy | Hold |
| 2023-04-26 | HC Wainwright & Co. | Upgrade | Buy | |
| 2023-02-01 | HC Wainwright & Co. | Upgrade | Buy | |
| 2022-12-09 | HC Wainwright & Co. | Upgrade | Buy | |
| 2022-12-08 | Maxim Group | Upgrade | Buy |
Profile
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2022-02-22 | CINCINNATI CORNERSTONE INVESTORS BWV I LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2023-05-08 | GARFIELD JON M | Chief Financial Officer | 100.00K | Stock Award(Grant) |
| 2023-05-08 | HENDERSON ERIN | Officer | 174.75K | Stock Award(Grant) |
| 2023-05-08 | HERNANDEZ JOSEPH | Chief Executive Officer | 2.80M | Stock Award(Grant) |
| 2023-05-30 | JEREMIC VUK | Director | 6.36K | Stock Award(Grant) |
| 2023-05-30 | RAMDEEN TIMOTHY R. | Director | 6.36K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Zurcher Kantonalbank (Zurich Cantonalbank) | 562.69K | 196.38K | 6.78% |
| 2024-09-29 | American Financial Group Inc. | 36.02K | 12.57K | 0.43% |
| 2024-09-29 | UBS Group AG | 12.98K | 4.53K | 0.16% |
| 2024-09-29 | Bank of America Corporation | 5.47K | 1.91K | 0.07% |
| 2024-09-29 | Fifth Third Bancorp | 2.40K | 838.00 | 0.03% |
| 2024-09-29 | Blackrock Inc. | 1.34K | 466.00 | 0.02% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Extended Market Index Fund | 4.04K | 1.41K | 0.05% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 1.84K | 641.00 | 0.02% |
| 2024-10-30 | Fidelity Total Market Index Fund | 1.82K | 635.00 | 0.02% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 166.00 | 57.00 | 0.00% |
Split
| Split | Date |
|---|---|
| 1 : 5 | 2026-03-25 |
| 1 : 85 | 2025-06-13 |
| 1 : 40 | 2024-09-24 |
| 1 : 1492 | 2016-09-28 |
